Format

Send to

Choose Destination
See comment in PubMed Commons below
Adv Cancer Res. 2004;91:1-30.

Imatinib as a paradigm of targeted therapies.

Author information

1
Howard Hughes Medical Institute, Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.

Abstract

Imatinib (Gleevec) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of the BCR-ABL tyrosine kinase as a therapeutic target in chronic myeloid leukemia and the steps in the development of an agent to specifically inactivate this abnormality. The clinical trials results are reviewed along with a description of resistance mechanisms. As imatinib also inhibits the tyrosine kinase activity of KIT and the platelet-derived growth factor receptors, the extension of imatinib to malignancies driven by these kinases will be described. Issues related to clinical trials of molecularly targeted agents are discussed, including patient and dose selection. Last, the translation of this paradigm to other malignancies is explored.

PMID:
15327887
DOI:
10.1016/S0065-230X(04)91001-9
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center